UBS lowered the firm’s price target on Braze (BRZE) to $43 from $48 and keeps a Buy rating on the shares. The firm “finally” has confidence that Braze can maintain organic revenue growth in the 20s, the analyst tells investors in a research note. UBS found the $17.5M EBIT raise, implying a margin of 3.5%, to be an incremental positive.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRZE:
- Braze price target raised to $52 from $50 at Citi
- Braze’s Strong Performance and Growth Potential: A Buy Rating Reinforced by Robust Revenue, Strategic Positioning, and Upside Potential
- Braze price target raised to $39 from $35 at Barclays
- Braze, Inc. Reports Strong Q2 2026 Financial Results
- Closing Bell Movers: Broadcom up 4%, Lululemon slips 15% after earnings